Potential effect of anti-inflammatory treatment on reducing the cardiovascular risk in rheumatoid arthritis

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 639-646

  Chighizola, Cecilia ^a,b   Schioppo, Tommaso ^a   Ingegnoli, Francesca ^a   Meroni, Pier Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

Anti TNF agents; Atherosclerosis; Cardiovascular disease; DMARDs; Inflammation; Novel biologic agents; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ACETYLSALICYLIC ACID; AZATHIOPRINE; CELECOXIB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETORICOXIB; GLUCOCORTICOID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISOLONE; RITUXIMAB; ROFECOXIB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG MEGADOSE; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOMODULATION; LIPID METABOLISM; LOW DRUG DOSE; MACROPHAGE; MONOCYTE; MONOTHERAPY; MORBIDITY; NONHUMAN; OSTEOARTHRITIS; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CYTOKINES; HUMANS; INFLAMMATION; PLAQUE, ATHEROSCLEROTIC; RISK FACTORS;

EID: 84864571781     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784503     Document Type: Review

References (94)

1. Young A, Koduri G, Batley M, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology 2007; 46: 350-7.
2. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years. Arthritis Rheum 2003; 48: 54-8.
3. Solomon DH, Goodson NJ, Katz JN, et al. Pattern of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1608-12.
4. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008; 10: R30.
5. Bartoloni E, Shoenfeld Y, Gerli R. Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin. Arthritis Care Res (Hoboken) 2011; 63: 178-83.
6. van Sijl AM, Peters MJ, Knol DK, et al. Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 2011; 40: 389-97.
7. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
8. Situnayake R, Sitas G. Dyslipidemia and Rheumatoid arthritis. Ann Rheum Dis 1997; 56: 341-2.
9. Lazarevic MB, Vitic J, Mladenovic V, Myones BL, Skosey JL, Swedler WI. Dyslipoproteinemia in the course of active rheumatoid arthritis. Semin Arthritis Rheum 1992; 22: 172-8.
10. Soltész P, Kerekes G, Dér H, et al. Comparative assessment of vascular function in autoimmune rheumatic diseases: considerations of prevention and treatment. Autoimmun Rev 2011; 10: 416-25.
11. Sarzi-Puttini P, Atzeni F, Gerli R, et al. Cardiac involvement in systemic rheumatic diseases: an update. Autoimmun Rev 2010; 9: 849-52.
12. Nussinovitch U, Shoenfeld Y. Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 2011; 10: 259-66.
13. Radovits BJ, Fransen J, Al Shamma S, Eijsbouts AM, van Riel PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010; 62: 362-70.
14. Bea F, Blessing E, Bennett BJ, et al. Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 2003; 60: 198-204.
15. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-9.
16. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102.
17. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-95.
18. ADAPT research group. Cardiovascular and cerebrovascular events in the randomized controlled Alzheimer's disease anti-inflammatory prevention trial (ADAPT). PloS Clin Trials 2006; 1: e33.
19. van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2009; 68: 668-73.
20. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology 2005; 44: 6677-80.
21. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006; 55: 531-6.
22. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analysis to determine cardiovascular risk associated with non-steroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 2008; 59: 1097-104.
23. Pham T, Gossec L, Constantin A, et al. Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines on published evidence and expert opinion. Joint Bone Spine 2006; 73: 379-87.
24. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J 1994; 70: 863-70.
25. del Rincon I, O'Leary DM, Haas RW, Escalante A. Effects of glucocorticoids o the arteries in rheumatoid arthritis. Arthritis Rheum 2004; 50: 3813-22.
26. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764-70.
27. Souverein PC, Berard A, van Staa TP, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart 2004; 90: 859-65.
28. Wolfe F, Michaud K. Corticosteroids increase the risk of diabetes mellitus in RA and contribute to the risk of myocardial infarction and heart failure (abstract). Ann Rheum Dis 2004; 63 (Suppl): SAT0379.
29. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006; 12: 3790-8.
30. Davis JM, Maradit-Kramers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis. Arthritis Rheum 2007; 56: 820-30.
31. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-Dahlqvist SR. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. J Rheumatol 1999; 26: 2562-71.
32. Maradit-Kremers H, Nicola P, Crowson C, Ballman K, Gabriel S. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005; 52: 412-20.
33. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Norther Sweden. Rheumatol 1997; 24: 445-51.
34. Boers M, Nurmohamed MT, Doelman CJA, et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 842-5.
35. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the third national health and nutrition examination survey. Arthritis Rheum 2005; 53: 528-35.
36. Davis JM, Maradit-Kramers H, Gabriel SE. Use of low dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: what is the true direction of effect? J Rheumatol 2005; 32: 10.
37. Abeles AM, Pillinger MH. Statins are anti-inflammatory and immunomodulatory agents: a future in rheumatologic therapy? Arthritis Rheum 2006; 54: 393-407.
38. Tristano AG, Fuller K. Immunomodulatory effects of statins and autoimmune rheumatic diseases: novel intracellular mechanism involved. Int Immuno pharmacol 2006; 6: 1833-46.
39. Bisoendial RJ, Stroes ES, Kastelein JJ, Tak PP. Targeting cardiovascular risk in rheumatoid arthritis: a dual role for statins. Nat Rev Rheumatol 2010; 6: 157-64.
40. Paraskevas KI. Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 2008; 27: 281-7.
41. McCarey D, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebocontrolled trial. Lancet 2004; 363.
42. Lodi S, Evans SJ, Egger P, Carpenter J. Is there an antiinflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database. Br J Clin Pharmacol 2010; 69: 85-94.
43. De Vera MA, Choi H, Abrahamowicz M, Kopec J, Goycochea-Robles MV, Lacaille D. Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population based cohort study. Ann Rheum Dis 2011; 70: 1020-24.
44. Jick SS, Choi H, Li L, McInnes IB, Sattar N. Hyperlipidaemia, statin use and the risk of developing rheumatoid arthritis. Ann Rheum Dis 2009; 68: 546-51.
45. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
46. van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology 2002; 41: 658-65.
47. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359: 1173-7.
48. Goodson NJ. The mortality association with DMARDs use in early inflammatory polyarthritis (abstract). Rheumatology 2008; 47: ii49.
49. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24: 469-80.
50. Prodanovic S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005; 52: 262-7.
51. Kremer JM, Reed G, White B, Baumgartner S, Lin S. Analysis of risk factors and effect of treatment on the development of cardiovascular disease in patients with rheumatoid arthritis (abstract). Ann Rheum Dis 2006; 65: 307.
52. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. Arthritis Res Ther 2006; 8: R151.
53. Reiss AB, Carsons SE, Anwar K, et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58: 3675-83.
54. Park YB, Choi HK, Kim MY, et al. Effects of anti-rheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 2002; 113: 188-93.
55. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is feature characteristic of patients with early rheumatoid arthritis: effect of early treatment-a prospective, controlled study. Arthritis Res Ther 2006; 8: R82.
56. Dessein PH, Joffe BI, Stanwix AE. Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study. Arthritis Res 2002; 4: R12.
57. Kockx M, Jessup W, Kritharides L. Cyclosporin A and atherosclerosis-cellular pathways in atherogenesis. Pharmacol Ther 2010; 128: 106-18.
58. Borigini MJ, Paulus HE. Innovative treatment approaches for rheumatoid arthritis. Combination therapy. Baillière's Clin Rheumatol 1995; 9: 689-710.
59. Fernandez-Miranda C, Guijarro C, de la Calle A et al. Lipid abnormalities in stable liver transplant recipients-effects of cyclosporine, tacrolimus and steroids. Transpl Int 1998;11:137-142
60. van den Borne BE, Landewé RB, Houkes I, et al. No increased risk of malignancies and mortality in cyclosporin A treated patients with rheumatoid arthritis. Arthritis Rheum 1998; 41: 1930-7.
61. Becker H, Potyka P, Weber C, Renelt M, Federlin K. T-helper cell subsets in patients with inflammatory rheumatic diseases undergoing immunosuppressive therapy. Immun Infekt 1991; 19: 26-7.
62. Roman MJ, Shanker B, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003; 349: 2399-406.
63. Boots JM, Christiaans MH, van Hooff JP. Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk. Drugs 2004; 64: 2047-73.
64. van Leuven SI, Kastelein JJ, Allison AC, Hayden MR, Stroes ES. Mycophenolate mofetil (MMF): firing at the atherosclerotic plaque from different angles? Cardiovasc Res 2006; 69: 341-7.
65. Schiff M, Beaulieu A, Scott DL, Rashford M. Mycophenolate mofetil in the treatment of adults with advanced rheumatoid arthritis: three 24-week, randomized, double-blind, placebo-or ciclosporin-controlled trials. Clin Drug Investig 2010; 30: 613-24.
66. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997; 350: 309-18.
67. Lafyatis R, York M, Marshak-Rothstein A. Antimalarial agents: closing the gate on Toll-like receptors? Arthritis Rheum 2006; 54: 3068-70.
68. Monaco C. The Tolls and dangers of atherosclerotic disease. Curr Pharm Biotechnol 2011 [Epub ahead of print].
69. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010; 69: 20-8.
70. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198-208.
71. Dixon WG, Simmons DP. What effects might anti-TNFβ treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFβ in cardiovascular pathophysiology. Ann Rheum Dis 2007; 66: 1132-6.
72. Ingegnoli F, Fantini F, Griffini S, et al. Anti-tumor necrosis factor alpha therapy normalises fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 254-7.
73. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-α blockade. J Autoimmun 2008; 31: 175-9.
74. Cugno M, Ingegnoli F, Gualtierotti R, Fantini F. Potential effect of anti-tumor necrosis factor-alpha treatment on reducing the cardiovascular risk related to rheumatoid arthritis. Curr Vasc Pharmacol 2010; 8: 285-92.
75. Hamdulay SS, Mason JC. Disease-modifying anti-rheumatic drugs: do they reduce cardiac complications of RA? Heart 2009; 95: 1471-2.
76. Weisman MH, Paulus HE, Burch FX, et al. Aplacebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. Rheumatology 2007; 46: 1122-5.
77. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 1213-8.
78. Carmona L, Descalzo MA, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007; 66: 880-5.
79. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. Curr Med Res Opin 2008; 24: 469-80.
80. Jacobsson LT, Turesson C, Nilsson JA, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66: 670-5.
81. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the british society for rheumatology biologics register. Arthrtis Rheum 2007; 56: 2905-12.
82. Radovits BJ, Popa-Diaconu DA, Popa C, et al. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1271-6.
83. Singh G, Vadhavkar S, Mithal A, Triadafilopoulos G. Combination TNF-inhibitor-methotrexate therapy is superior to methotrexate monotherapy in reducing the risk of acute myocardial infarction in patients with rheumatoid arthritis. Arthritis Rheum 2007; 56: S535.
84. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and non-pharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohortand nested case-control analysis. Arthritis Rheum 2008; 58: 2612-21.
85. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. Arthritis Rheum 2008; 59: 1090-6.
86. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 2008; 58: 667-77.
87. Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNFalpha antagonists. Rheumatology 2007; 46: 1688-93.
88. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. Rheumatol Int 2007; 27: 369-73.
89. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factoralpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-41.
90. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate to severe heart failure. Circulation 2003; 107: 3133-40.
91. Popa C, van den Hoogen FHJ, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.
92. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010; 5: e14328.
93. Kawashiri SY, Kawakami A, Yamasaki S, et al. Effects of the antiinterleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 451-6.
94. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR. et al. Short-term improvement of endothelial function in rituximabtreated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum 2008; 59: 1821-4.